At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
ALLN-177drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
In Brief
A Phase 2 clinical trial evaluating ALLN-177 for Hyperoxaluria and Nephrolithiasis. Completed, enrolled 16 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of ALLN-177 to reduce urinary oxalate excretion in patients with recurring kidney stones and enteric or idiopathic hyperoxaluria.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperoxaluria, Nephrolithiasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedNov 2014
Primary CompletionJan 2015
Study CompletionFeb 2015
TodayJul 2026
First PostedNov 13, 2014
Enrollment StartSep 1, 2014
Primary CompletionJan 1, 2015
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.6 years ago
Interventions
ALLN-177drug
ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.